Inadequate gonadal replacement in patients with Turner syndrome may result in pituitary volume enlargement

Autor: Gamze Akkus, Irem Kolsuz, Sinan Sozutok, Bilen Onan, Barıs Karagun, Mehtap Evran, Murat Sert, Tamer Tetiker
Rok vydání: 2023
Předmět:
Zdroj: Current Medical Imaging Formerly Current Medical Imaging Reviews. 19
ISSN: 1573-4056
DOI: 10.2174/1573405619666230223170130
Popis: aims: We aim to evaluate pituitary volume of patients with Turner Syndrome who received adequate hormone replacement therapy or did not receive this therapy. In addition, we also compared the measurements of pituitary volumes of the patients with TS and healthy control patients. background: Most patients with Turner Syndrome need hormone replacement therapy for puberty induction. However, it is not known whether inadequate hormone replacement therapy affects pituitary. objective: Patients with Turner Syndrome (n=35) and 20 healthy control (age/gender matched) subjects were included. MRI imaging of the pituitary was used to calculate pituitary volumes. method: According to the estradiol regimen; patients were divided into two groups;(i) those treated with low-dose conjugated oestrogen (CE, 0.625 mg) and (ii) those treated with combination therapy (ethinyl estradiol+sipropterone acetate; 35 mcg/2 mg). Pituitary volumes were calculated according to pituitary borders and their distances to each other via pituitary MRI. result: Pituitary hyperplasia (0.58±0.15 cm3 vs 0.40±0.17 cm3) was determined in patients with low dose conjugated estrogen compared to the other patients or healthy control subjects (0.42±0.16 cm3) (p=0.005). Serum FSH levels of the patients treated with low dose CE were also higher compared to the patients who received combination therapy (p=0.001). conclusion: Inadequate hormone replacement therapy can cause devastating effects on the bones and uterine health and disrupts the pituitary structure as well. other: The goal of optimal hormone is induction of puberty and maintaining secondary sex characteristics or receiving peak bone mass.). In spite of all of these recommendations, the most suitable replacement therapy, timing of replacement, dosing, route of administration and possible beneficial effects are still unclear
Databáze: OpenAIRE